Ken Griffin Xtl Biopharmaceuticals LTD Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Xtl Biopharmaceuticals LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 25,211 shares of XTLB stock, worth $27,984. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,211

Holding current value

$27,984

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.1 - $2.09 $27,732 - $52,690	25,211 New	25,211 $30,000
Q2 2024 Aug 14, 2024	BUY	$2.04 - $3.33 $3,680 - $6,007	1,804 Added 13.23%	15,435 $37,000
Q1 2024 May 15, 2024	BUY	$0.8 - $3.07 $10,904 - $41,847	13,631 New	13,631 $38,000
Q3 2021 Nov 15, 2021	BUY	$3.43 - $5.2 $43,907 - $66,565	12,801 New	12,801 $56,000
Q4 2019 Feb 14, 2020	SELL	$1.2 - $1.67 $21,904 - $30,484	-18,254 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$1.44 - $2.1 $1,356 - $1,978	942 Added 5.44%	18,254 $26,000
Q2 2018 Aug 10, 2018	BUY	$1.55 - $2.41 $26,833 - $41,721	17,312 New	17,312 $0

Others Institutions Holding XTLB

# of Institutions

Shares Held

447K

Call Options Held

Put Options Held

View Full List

About XTL BIOPHARMACEUTICALS LTD

Ticker XTLB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,449,060
Market Cap $6.05M
Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...

More about XTLB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account